<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-title>Diabetologia</journal-title><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1413</article-id><article-id pub-id-type="doi">10.1007/s00125-009-1413-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Combined effects of single-nucleotide polymorphisms in <italic>GCK</italic>, <italic>GCKR</italic>, <italic>G6PC2</italic> and <italic>MTNR1B</italic> on fasting plasma glucose and type 2 diabetes risk</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Reiling</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van &#x02019;t Riet</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Groenewoud</surname><given-names>M. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Welschen</surname><given-names>L. M. C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Hove</surname><given-names>E. C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nijpels</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maassen</surname><given-names>J. A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dekker</surname><given-names>J. M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>&#x02019;t Hart</surname><given-names>L. M.</given-names></name><address><email>l.m.t_hart@lumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Molecular Cell Biology, Leiden University Medical Centre, PO Box 9600, 2300RC Leiden, the Netherlands </aff><aff id="Aff2"><label>2</label>EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, the Netherlands </aff><aff id="Aff3"><label>3</label>Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, the Netherlands </aff><aff id="Aff4"><label>4</label>Department of General Practice, VU University Medical Centre, Amsterdam, the Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>6</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><volume>52</volume><issue>9</issue><fpage>1866</fpage><lpage>1870</lpage><history><date date-type="received"><day>10</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><sec><title>Aims/hypothesis</title><p>Variation in fasting plasma glucose (FPG) within the normal range is a known risk factor for the development of type 2 diabetes. Several reports have shown that genetic variation in the genes for glucokinase (<italic>GCK</italic>), glucokinase regulatory protein (<italic>GCKR</italic>), islet-specific glucose 6 phosphatase catalytic subunit-related protein (<italic>G6PC2</italic>) and melatonin receptor type 1B (<italic>MTNR1B</italic>) is associated with FPG. In this study we examined whether these loci also contribute to type 2 diabetes susceptibility.</p></sec><sec><title>Methods</title><p>A random selection from the Dutch New Hoorn Study was used for replication of the association with FGP (2,361 non-diabetic participants). For the genetic association study we extended the study sample with 2,628 participants with type 2 diabetes. Risk allele counting was used to calculate a four-gene risk allele score for each individual.</p></sec><sec><title>Results</title><p>Variants of the <italic>GCK</italic>, <italic>G6PC2</italic> and <italic>MTNR1B</italic> genes but not <italic>GCKR</italic> were associated with FPG (all, <italic>p</italic>&#x02009;&#x02264;&#x02009;0.001; <italic>GCKR</italic>, <italic>p</italic>&#x02009;=&#x02009;0.23). Combining these four genes in a risk allele score resulted in an increase of 0.05&#x000a0;mmol/l (0.04&#x02013;0.07) per additional risk allele (<italic>p</italic>&#x02009;=&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;13</sup>). Furthermore, participants with less than three or more than five risk alleles showed significantly different type 2 diabetes susceptibility compared with the most common group with four risk alleles (OR 0.77 [0.65&#x02013;0.93], <italic>p</italic>&#x02009;=&#x02009;0.005 and OR 2.05 [1.50&#x02013;2.80], <italic>p</italic>&#x02009;=&#x02009;4&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup> respectively). The age at diagnosis was also significantly associated with the number of risk alleles (<italic>p</italic>&#x02009;=&#x02009;0.009).</p></sec><sec><title>Conclusions</title><p>A combined risk allele score for single-nucleotide polymorphisms in four known FPG loci is significantly associated with FPG and HbA<sub>1c</sub> in a Dutch population-based sample of non-diabetic participants. Carriers of low or high numbers of risk alleles show significantly different risks for type 2 diabetes compared with the reference group.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00125-009-1413-9) contains supplementary material, which is available to authorised users.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Fasting plasma glucose</kwd><kwd>Genetics</kwd><kwd>Single-nucleotide polymorphism</kwd><kwd>Type 2 diabetes</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Variation in fasting plasma glucose (FPG) levels within the normal range are associated with an increased risk of developing type 2 diabetes and coronary heart disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Furthermore, it is known that FPG is partially genetically determined [<xref ref-type="bibr" rid="CR3">3</xref>]. Several loci influencing FPG levels have been identified. These loci encode glucokinase (<italic>GCK</italic>), glucokinase regulatory protein (<italic>GCKR</italic>) and islet-specific glucose 6 phosphatase catalytic subunit-related protein (<italic>G6PC2</italic>) [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Recently, the gene encoding melatonin receptor type 1B (<italic>MTNR1B</italic>) was identified as a fourth locus influencing FPG [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. In this study we investigated the combined effect of these loci on FPG levels in the Netherlands and analysed their single and combined effects on the risk of type 2 diabetes.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study samples</title><p><bold>Study sample for continuous trait analysis</bold> For this part of the study we used participants from the ongoing New Hoorn Study, a population-based cohort study in the Netherlands, which examines potential determinants of glucose intolerance and related disorders [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. From this study, 2,361 non-diabetic white participants (46% male, aged 53&#x02009;&#x000b1;&#x02009;7&#x000a0;years) were selected from the original random sample of the population register of the town of Hoorn, the Netherlands. Glucose tolerance status was assessed with OGTTs using the 1999 WHO criteria [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p><bold>Case&#x02013;control sample for genetic association with type 2 diabetes</bold> As a control sample we used all participants with normal glucose tolerance from the above-mentioned sample (<italic>n</italic>&#x02009;=&#x02009;2,041). Subjects with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG; <italic>n</italic>&#x02009;=&#x02009;320) were excluded from the control group because they have an increased risk of type 2 diabetes.For the case sample we used all known (<italic>n</italic>&#x02009;=&#x02009;90) and newly identified (<italic>n</italic>&#x02009;=&#x02009;90) cases from the New Hoorn Study. To improve power we added cases from Diabetes Care System West Friesland (DCS, <italic>n</italic>&#x02009;=&#x02009;1,906) [<xref ref-type="bibr" rid="CR17">17</xref>]. The DCS aims to improve diabetes care by coordinating diabetes care, involving all caregivers and providing education for patients in order to improve patient empowerment. Patients are referred to the DCS by their physicians and are from the same geographical region as those taking part in the New Hoorn Study. We also included 542 type 2 diabetes patients from the diabetes clinics at Leiden University Medical Centre (Leiden, the Netherlands) and VU University Medical Centre (Amsterdam, the Netherlands), who were referred to the clinic by their physicians. In total we selected 2,628 participants with type 2 diabetes (55% males, aged 64&#x02009;&#x000b1;&#x02009;11&#x000a0;years) for the case&#x02013;control study. All participants in our study were of white ethnicity. The study was approved by the appropriate medical ethics committees and was in accordance with the principles of the Declaration of Helsinki.</p></sec><sec id="Sec4"><title>Genotyping and quality control</title><p>Based on previous publications, we selected the single-nucleotide polymorphisms (SNPs) rs1799884 in <italic>GCK</italic> [<xref ref-type="bibr" rid="CR4">4</xref>], rs1260326 (P446L) in <italic>GCKR</italic> [<xref ref-type="bibr" rid="CR7">7</xref>], rs560887 in <italic>G6PC2</italic> [<xref ref-type="bibr" rid="CR9">9</xref>] and rs10830963 in <italic>MTNR1B</italic> [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>] for genotyping with Taqman SNP genotyping assay (Applied Biosystems, Foster City, CA, USA). All genotype frequencies were similar between the case subgroups. For quality control the allelic discrimination plots were visually observed for good clustering. Plates with bad clustering or a success rate below 95% were repeated. Next, we assessed Hardy&#x02013;Weinberg equilibrium (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05) and genotyped approximately 5% duplicate samples, which all showed identical genotypes.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>Differences in FPG and other clinical variables (HbA<sub>1c</sub>, 2&#x000a0;h glucose, triacylglycerol, LDL, HDL, total cholesterol, BMI and waist&#x02013;hip ratio) were analysed in non-diabetic participants using linear regression, adjusted for BMI, age and sex as possible confounders. All analyses were performed using an additive model, because previous studies had shown that this model was the best fit. In order to combine the effects of all SNPs, risk alleles were counted and used as a sum score [<xref ref-type="bibr" rid="CR18">18</xref>]. A risk allele was defined as an allele that results in an increased FPG as described in the literature. Differences in genotype distribution, allele frequency and risk allele scores between participants with normal glucose tolerance and those with type 2 diabetes were compared using standard contingency tables with Fisher&#x02019;s exact test, and allelic ORs were calculated with logistic regression adjusted for age, sex and BMI. Subjects with either IGT or IFG were excluded from this analysis. Using Bonferroni correction for multiple hypothesis testing, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 was considered statistically significant for association of FPG loci with clinical variables (36 tests). For the case&#x02013;control study, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 was considered significant (four tests). All statistics were calculated using SPSS 16.0 (SPSS, Chicago, IL, USA).</p></sec><sec id="Sec6"><title>Power calculations</title><p>Power calculations were performed using Quanto [<xref ref-type="bibr" rid="CR19">19</xref>]. We had an estimated power of 80% to detect a minimal per allele effect in clinical variables between 0.056 and 0.069&#x000a0;mmol/l, depending on allele frequency (<italic>&#x003b1;</italic>&#x02009;=&#x02009;0.001). For the association study with type 2 diabetes we had an estimated power of 80% to detect a minimal OR between 1.13 and 1.16 for single gene effects (<italic>&#x003b1;</italic>&#x02009;=&#x02009;0.01). For all power calculations we assumed an additive model.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>All SNPs passed quality control guidelines. Associations between SNPs and clinical variables were analysed in the non-diabetic participants only. Results of association with FPG levels were comparable to those reported in the literature (all <italic>p</italic>&#x02009;&#x02264;&#x02009;0.001), except for <italic>GCKR</italic>, for which we could not detect a significant effect on FPG levels (<italic>p</italic>&#x02009;=&#x02009;0.23; results shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). However, <italic>GCKR</italic> showed nominal evidence for decreased 2&#x000a0;h glucose, but did not reach a formally significant <italic>p</italic> value (<italic>p</italic>&#x02009;=&#x02009;0.008; see Electronic supplementary material [ESM] Table&#x000a0;<xref ref-type="supplementary-material" rid="MOESM1">1</xref>). Furthermore, <italic>GCK</italic> and <italic>G6PC2</italic> showed increased HbA<sub>1c</sub> levels (<italic>p</italic>&#x02009;=&#x02009;5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;8</sup> and 3&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup>; ESM Table&#x000a0;<xref ref-type="supplementary-material" rid="MOESM1">1</xref>). In line with our FPG results, <italic>GCKR</italic> was not associated with HbA<sub>1c</sub> levels (<italic>p</italic>&#x02009;=&#x02009;0.50). However, we did confirm the previously reported association of the T allele of rs1260326 (<italic>GCKR</italic>) with increased triacylglycerol levels (<italic>p</italic>&#x02009;=&#x02009;9&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;7</sup>; ESM Table&#x000a0;<xref ref-type="supplementary-material" rid="MOESM1">1</xref>) [<xref ref-type="bibr" rid="CR5">5</xref>]. Other clinical variables were not associated with any of the analysed variants (ESM Table&#x000a0;<xref ref-type="supplementary-material" rid="MOESM1">1</xref>). We analysed the combined effect of all SNPs by calculating the risk allele score for each individual. We observed a combined effect of the risk alleles on FPG levels. The increase in FPG level per additional risk allele was 0.05 (0.04&#x02013;0.07)&#x000a0;mmol/l, <italic>p</italic>&#x02009;=&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;13</sup> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). A similar result was observed for HbA<sub>1c</sub>: 0.03% (0.02&#x02013;0.04%) increase per additional risk allele, <italic>p</italic>&#x02009;=&#x02009;5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;10</sup> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). We also analysed whether the rate of the age-related increase in FPG was affected by the number of risk alleles. However, we did not observe any divergence in these rates between the different risk allele scores in our cross-sectional data set (ESM Fig.&#x000a0;<xref ref-type="supplementary-material" rid="MOESM3">1</xref>). Separate analysis of only the participants with normal glucose tolerance (<italic>n</italic>&#x02009;=&#x02009;2,041) did not alter any of the results (data not shown). <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Association of SNPs with FPG (<italic>n</italic>&#x02009;=&#x02009;2,361) and type 2 diabetes (<italic>n</italic>&#x02009;=&#x02009;4,669)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">SNP</th><th rowspan="2">Locus</th><th rowspan="2">Risk allele</th><th colspan="3">FPG, mmol/l (genotype count)</th><th rowspan="2">Effect per allele, mmol/l (95% CI)</th><th rowspan="2"><italic>p</italic> value</th><th>T2D OR</th><th rowspan="2"><italic>p</italic> value</th></tr><tr><th>AA</th><th>AB</th><th>BB</th><th>95% CI</th></tr></thead><tbody><tr><td>rs1799884</td><td><italic>GCK</italic></td><td>A</td><td char="(" align="char">5.39&#x02009;&#x000b1;&#x02009;0.01 (1,523)</td><td char="(" align="char">5.45&#x02009;&#x000b1;&#x02009;0.02 (620)</td><td char="(" align="char">5.47&#x02009;&#x000b1;&#x02009;0.05 (65)</td><td>0.06 (0.03, 0.09)</td><td>0.001</td><td>1.12 (1.00, 1.25)</td><td char="." align="char">0.06</td></tr><tr><td>rs1260326</td><td><italic>GCKR</italic></td><td>C</td><td char="(" align="char">5.35&#x02009;&#x000b1;&#x02009;0.03 (267)</td><td char="(" align="char">5.39&#x02009;&#x000b1;&#x02009;0.01 (956)</td><td char="(" align="char">5.38&#x02009;&#x000b1;&#x02009;0.01 (924)</td><td>0.01 (&#x02212;0.02, 0.03)</td><td>0.23</td><td>0.94 (0.86, 1.02)</td><td char="." align="char">0.13</td></tr><tr><td>rs560887</td><td><italic>G6PC2</italic></td><td>G</td><td char="(" align="char">5.32&#x02009;&#x000b1;&#x02009;0.03 (218)</td><td char="(" align="char">5.36&#x02009;&#x000b1;&#x02009;0.01 (930)</td><td char="(" align="char">5.43&#x02009;&#x000b1;&#x02009;0.01 (1,077)</td><td>0.06 (0.04, 0.09)</td><td>5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup></td><td>0.96 (0.87, 1.05)</td><td char="." align="char">0.32</td></tr><tr><td>rs10830963</td><td><italic>MTNR1B</italic></td><td>G</td><td char="(" align="char">5.37&#x02009;&#x000b1;&#x02009;0.01 (1,269)</td><td char="(" align="char">5.44&#x02009;&#x000b1;&#x02009;0.01 (891)</td><td char="(" align="char">5.52&#x02009;&#x000b1;&#x02009;0.04 (135)</td><td>0.08 (0.05, 0.11)</td><td>7&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;8</sup></td><td>1.12 (1.02, 1.23)</td><td char="." align="char">0.02</td></tr></tbody></table><table-wrap-foot><p>Estimated FPG levels (mean&#x02009;&#x000b1;&#x02009;SD) per genotype are adjusted for age, sex and BMI</p><p>Effect per allele on FPG levels and <italic>p</italic> values, adjusted for age, sex and BMI, were generated by linear regression</p><p>Because of differences in the number of participants genotyped for each of the loci, the estimated means are slightly different</p><p>The B genotype represents the risk allele</p><p>Odds ratios are for associations of independent SNPs with type 2 diabetes and were calculated based on allele frequency in 2,041 controls and 2,628 type 2 diabetes participants</p><p>Subjects with IGT or IFG were excluded from this analysis</p><p>T2D, type 2 diabetes</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Combined effect of <italic>GCK</italic>, <italic>GCKR</italic>, <italic>G6PC2</italic> and <italic>MTNR1B</italic> on FPG and HbA<sub>1c</sub> in non-diabetic participants from the New Hoorn Study. <bold>a</bold> Fasting plasma glucose. Numbers within the bars are numbers of participants per allele group. The per allele effect was 0.05 (0.04&#x02013;0.07)&#x02009; mmol/l, <italic>p</italic>&#x02009;=&#x02009;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;13</sup>). Error bars represent 95% CI. <bold>b</bold> HbA<sub>1c</sub>. Numbers within the bars represent the number of participants per allele group. The per allele effect was 0.03% (0.02&#x02013;0.04%), <italic>p</italic>&#x02009;=&#x02009;5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;10</sup> Error bars represent 95% CI</p></caption><graphic position="anchor" xlink:href="125_2009_1413_Fig1_HTML" id="MO1"/></fig></p><p>Next, we analysed the association of the single gene variants and the risk allele score with type 2 diabetes susceptibility. Only rs10830963 (<italic>MTNR1B</italic>) and rs1799884 (<italic>GCK</italic>) showed weak evidence for association with type 2 diabetes (<italic>p</italic>&#x02009;=&#x02009;0.02 and <italic>p</italic>&#x02009;=&#x02009;0.06 respectively; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and ESM Table&#x000a0;<xref ref-type="supplementary-material" rid="MOESM2">2</xref>). Risk allele scores were calculated for the participants with normal glucose tolerance and those with type 2 diabetes and all risk allele groups were compared with the reference group having four risk alleles, since this was the most common group (31%). The lower risk allele groups showed a protective effect on type 2 diabetes, while the risk allele groups with more than four risk alleles showed an increased risk of type 2 diabetes (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Those with fewer than three risk alleles had a significantly reduced risk of type 2 diabetes (OR 0.77 [0.65&#x02013;0.93], <italic>p</italic>&#x02009;=&#x02009;0.005) whereas those with more than five had a significantly increased risk of type 2 diabetes compared with the reference group (OR 2.05 [1.50&#x02013;2.80], <italic>p</italic>&#x02009;=&#x02009;4&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup>). Adjustment for age, sex and BMI did not alter the results. <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Association of risk allele scores with type 2 diabetes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Alleles</th><th colspan="2">Count (frequency)</th><th rowspan="2">Age at diagnosis<sup>a</sup> (years, mean&#x02009;&#x000b1;&#x02009;SD)</th><th rowspan="2">OR for T2D (95% CI)</th><th rowspan="2"><italic>p</italic> value OR for T2D</th></tr><tr><th>Controls (<italic>n</italic>&#x02009;=&#x02009;2,041)</th><th>Cases (<italic>n</italic>&#x02009;=&#x02009;2,628)</th></tr></thead><tbody><tr><td>0 or 1</td><td char="(" align="char">76 (4.2)</td><td char="(" align="char">115 (4.9)</td><td char="&#x000b1;" align="char">57.5&#x02009;&#x000b1;&#x02009;1.1</td><td align="center">0.75 (0.55&#x02013;1.02)</td><td>0.07</td></tr><tr><td>2</td><td char="(" align="char">243 (13.5)</td><td char="(" align="char">352 (15.0)</td><td char="&#x000b1;" align="char">57.3&#x02009;&#x000b1;&#x02009;0.6</td><td align="center">0.78 (0.64&#x02013;0.95)</td><td>0.02</td></tr><tr><td>3</td><td char="(" align="char">522 (29.0)</td><td char="(" align="char">667 (28.4)</td><td char="&#x000b1;" align="char">56.1&#x02009;&#x000b1;&#x02009;0.5</td><td char="(" align="char">0.89 (0.76&#x02013;1.04)</td><td>0.14</td></tr><tr><td>4</td><td char="(" align="char">605 (33.6)</td><td char="(" align="char">685 (29.1)</td><td char="&#x000b1;" align="char">55.6&#x02009;&#x000b1;&#x02009;0.4</td><td>1.00</td><td>ref</td></tr><tr><td>5</td><td char="(" align="char">288 (16.0)</td><td char="(" align="char">381 (16.2)</td><td char="&#x000b1;" align="char">56.1&#x02009;&#x000b1;&#x02009;0.6</td><td char="(" align="char">1.17 (0.97&#x02013;1.41)</td><td>0.11</td></tr><tr><td>6&#x02013;8</td><td char="(" align="char">65 (3.6)</td><td char="(" align="char">151 (6.4)</td><td char="&#x000b1;" align="char">52.9&#x02009;&#x000b1;&#x02009;0.9</td><td char="(" align="char">2.05 (1.50&#x02013;2.80)</td><td>4&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Age at diagnosis was available for 2,132 participants with type 2 diabetes</p><p><italic>&#x003b2;</italic><sub>age at diagnosis</sub>&#x02009;=&#x02009;&#x02212;0.46 (&#x02212;0.80 to &#x02212;0.11) years, <italic>p</italic>&#x02009;=&#x02009;0.009 adjusted for sex</p><p>The OR for type 2 diabetes and <italic>p</italic> value were compared with the four risk alleles group as a reference (ref)</p><p>The OR for type 2 diabetes for less than three vs four risk alleles was 0.77 (0.65&#x02013;0.93), <italic>p</italic>&#x02009;=&#x02009;0.005 and the OR for type 2 diabetes for more than four vs four risk alleles was 1.33 (1.12&#x02013;1.58), <italic>p</italic>&#x02009;=&#x02009;0.001</p><p>T2D, type 2 diabetes</p></table-wrap-foot></table-wrap></p><p>We also noted a significant correlation with the age at diagnosis of type 2 diabetes in our study sample. We observed a per allele effect of &#x02212;0.46 (&#x02212;0.80 to &#x02212;0.11) years in age at diagnosis per additional risk allele (<italic>p</italic>&#x02009;=&#x02009;0.009; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). At the extremes of the distribution, i.e. zero or one vs six to eight risk alleles, there was a difference of almost 4.5&#x000a0;years in age at diagnosis between the two groups (<italic>p</italic>&#x02009;=&#x02009;0.002; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>Several studies have shown that SNPs in <italic>GCK</italic>, <italic>GCKR</italic>, <italic>G6PC2</italic> and <italic>MTNR1B</italic> are associated with FPG levels [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In this study we replicated these findings in a Dutch population, with the exception of the association of <italic>GCKR</italic> with FPG. However, our results for <italic>GCKR</italic> are in the same direction as those of most other studies and it should be noted that some other recent publications reported considerable variability in effect size between different samples [<xref ref-type="bibr" rid="CR8">8</xref>] or failed to replicate this observation [<xref ref-type="bibr" rid="CR11">11</xref>]. <italic>GCK</italic> and <italic>G6PC2</italic> were associated with HbA<sub>1c</sub> in our study, which confirms previous observations [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p>We observed a significant combined effect of all variants on FPG levels. This confirms a recent observation in a French study [<xref ref-type="bibr" rid="CR13">13</xref>]. The association of FPG levels with the risk allele count was also reflected in increased HbA<sub>1c</sub> levels, arguing against previous findings in which it was suggested that FPG and HbA<sub>1c</sub> have independent underlying risk loci [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Our cross-sectional data suggest that these loci cause a physiological disturbance of glucose homeostasis by raising the set point of insulin secretion, leading to an elevation of FPG depending on the number of risk alleles present, which is not further affected by ageing. However, longitudinal studies and a wider age span would be needed to confirm this observation.</p><p>To our knowledge, this is the first report showing that the analysed loci have a combined effect on type 2 diabetes susceptibility, although the contribution of each individual variant to the risk of type 2 diabetes is very low or undetectable (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Our data show that carriers of fewer than three risk alleles are at decreased risk of type 2 diabetes whereas those with more than five risk alleles have increased susceptibility to type 2 diabetes compared with the most common risk allele group of four risk alleles. We also noted a significantly different age at diagnosis between the different groups, indicating that the number of risk alleles also influences the age at which the disease becomes manifest. This might also have implications for the development of complications. If replicated, our results imply that these loci not only influence FPG levels, probably through an altered set point for glucose at which an insulin response is elicited, but also jointly increase the risk of type 2 diabetes and the age at diagnosis.</p><p>In conclusion, we replicated the combined effect of <italic>GCK</italic>, <italic>GCKR</italic>, <italic>G6PC2</italic> and <italic>MTNR1B</italic> risk alleles with FPG. Furthermore, we showed that the risk allele score is also associated with HbA<sub>1c</sub> and that carriers of a low or high number of risk alleles have significantly different susceptibilities to the development of type 2 diabetes and age at diagnosis of the disease.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><supplementary-material id="N0x1ca6950N0x2f975d8" content-type="local-data"><p>Below is the link to the electronic supplementary material. </p><media xlink:href="125_2009_1413_MOESM1_ESM.pdf" id="MOESM1" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;1</label><caption><p>(PDF 21&#x000a0;kb)</p></caption></media><media xlink:href="125_2009_1413_MOESM2_ESM.pdf" id="MOESM2" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;2</label><caption><p>(PDF 11&#x000a0;kb)</p></caption></media><media xlink:href="125_2009_1413_MOESM3_ESM.pdf" id="MOESM3" mimetype="application" mime-subtype="pdf"><label>ESM Fig.&#x000a0;1</label><caption><p>(PDF 30&#x000a0;kb)</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to acknowledge all participants for their cooperation. This project was funded by The Netherlands Organization for Scientific Research, ZonMW RIDE program and the Dutch Diabetes Research Foundation.</p><p><bold>Duality of interest</bold> The authors declare that there is no duality of interest associated with this manuscript.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vegt</surname><given-names>F</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name><name><surname>Ruhe</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study</article-title><source>Diabetologia</source><year>1999</year><volume>42</volume><fpage>926</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1007/s001250051249</pub-id></citation><citation citation-type="display-unstructured">de Vegt F, Dekker JM, Ruhe HG et al (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42:926&#x02013;931 <pub-id pub-id-type="pmid">10491751</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vegt</surname><given-names>F</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name><name><surname>Jager</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2109</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1001/jama.285.16.2109</pub-id></citation><citation citation-type="display-unstructured">de Vegt F, Dekker JM, Jager A et al (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 285:2109&#x02013;2113 <pub-id pub-id-type="pmid">11311100</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snieder</surname><given-names>H</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Doornen</surname><given-names>LJ</given-names></name><name><surname>Neale</surname><given-names>MC</given-names></name></person-group><article-title>Bivariate genetic analysis of fasting insulin and glucose levels</article-title><source>Genet Epidemiol</source><year>1999</year><volume>16</volume><fpage>426</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2272(1999)16:4&#x0003c;426::AID-GEPI8&#x0003e;3.0.CO;2-B</pub-id></citation><citation citation-type="display-unstructured">Snieder H, Boomsma DI, van Doornen LJ, Neale MC (1999) Bivariate genetic analysis of fasting insulin and glucose levels. Genet Epidemiol 16:426&#x02013;446 <pub-id pub-id-type="pmid">10207722</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Shields</surname><given-names>B</given-names></name><etal/></person-group><article-title>Genetic regulation of birth weight and fasting glucose by a common polymorphism in the islet cell promoter of the glucokinase gene</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>576</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.2.576</pub-id></citation><citation citation-type="display-unstructured">Weedon MN, Frayling TM, Shields B et al (2005) Genetic regulation of birth weight and fasting glucose by a common polymorphism in the islet cell promoter of the glucokinase gene. Diabetes 54:576&#x02013;581 <pub-id pub-id-type="pmid">15677518</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><collab>The Diabetes Genetics Initiative of the Broad Institute of MIT and Harvard and Lund University and Novartis Institutes for BioMedical Research</collab></person-group><article-title>Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>1331</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1126/science.1142358</pub-id></citation><citation citation-type="display-unstructured">The Diabetes Genetics Initiative of the Broad Institute of MIT and Harvard and Lund University and Novartis Institutes for BioMedical Research (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331&#x02013;1336 <pub-id pub-id-type="pmid">17463246</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sparso</surname><given-names>T</given-names></name><name><surname>Andersen</surname><given-names>G</given-names></name><name><surname>Nielsen</surname><given-names>T</given-names></name><etal/></person-group><article-title>The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s00125-007-0865-z</pub-id></citation><citation citation-type="display-unstructured">Sparso T, Andersen G, Nielsen T et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70&#x02013;75 <pub-id pub-id-type="pmid">18008060</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaxillaire</surname><given-names>M</given-names></name><name><surname>Cavalcanti-Proenca</surname><given-names>C</given-names></name><name><surname>Dechaume</surname><given-names>A</given-names></name><etal/></person-group><article-title>The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2253</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.2337/db07-1807</pub-id></citation><citation citation-type="display-unstructured">Vaxillaire M, Cavalcanti-Proenca C, Dechaume A et al (2008) The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 57:2253&#x02013;2257 <pub-id pub-id-type="pmid">18556336</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orho-Melander</surname><given-names>M</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Guiducci</surname><given-names>C</given-names></name><etal/></person-group><article-title>Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>3112</fpage><lpage>3121</lpage><pub-id pub-id-type="doi">10.2337/db08-0516</pub-id></citation><citation citation-type="display-unstructured">Orho-Melander M, Melander O, Guiducci C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112&#x02013;3121 <pub-id pub-id-type="pmid">18678614</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouatia-Naji</surname><given-names>N</given-names></name><name><surname>Rocheleau</surname><given-names>G</given-names></name><name><surname>Lommel</surname><given-names>L</given-names></name><etal/></person-group><article-title>A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels</article-title><source>Science</source><year>2008</year><volume>320</volume><fpage>1085</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1126/science.1156849</pub-id></citation><citation citation-type="display-unstructured">Bouatia-Naji N, Rocheleau G, van Lommel L et al (2008) A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320:1085&#x02013;1088 <pub-id pub-id-type="pmid">18451265</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Guo</surname><given-names>NN</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>ED</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name></person-group><article-title>CP1 domain in <italic>Escherichia coli</italic> leucyl-tRNA synthetase is crucial for its editing function</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>6726</fpage><lpage>6731</lpage><pub-id pub-id-type="doi">10.1021/bi000108r</pub-id></citation><citation citation-type="display-unstructured">Chen JF, Guo NN, Li T, Wang ED, Wang YL (2000) CP1 domain in Escherichia coli leucyl-tRNA synthetase is crucial for its editing function. Biochemistry 39:6726&#x02013;6731 <pub-id pub-id-type="pmid">10828991</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prokopenko</surname><given-names>I</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Variants in MTNR1B influence fasting glucose levels</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/ng.290</pub-id></citation><citation citation-type="display-unstructured">Prokopenko I, Langenberg C, Florez JC et al (2009) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41:77&#x02013;81 <pub-id pub-id-type="pmid">19060907</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Nagorny</surname><given-names>CL</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/ng.288</pub-id></citation><citation citation-type="display-unstructured">Lyssenko V, Nagorny CL, Erdos MR et al (2009) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82&#x02013;88 <pub-id pub-id-type="pmid">19060908</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouatia-Naji</surname><given-names>N</given-names></name><name><surname>Bonnefond</surname><given-names>A</given-names></name><name><surname>Cavalcanti-Proenca</surname><given-names>C</given-names></name><etal/></person-group><article-title>A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/ng.277</pub-id></citation><citation citation-type="display-unstructured">Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C et al (2009) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89&#x02013;94 <pub-id pub-id-type="pmid">19060909</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riet</surname><given-names>E</given-names></name><name><surname>Rijkelijkhuizen</surname><given-names>JM</given-names></name><name><surname>Nijpels</surname><given-names>G</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name></person-group><article-title>Limited agreement between HbA1c and glucose in the general Dutch population: The New Hoorn Study</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>S164</fpage></citation><citation citation-type="display-unstructured">van &#x02019;t Riet E, Rijkelijkhuizen JM, Nijpels G, Dekker JM (2008) Limited agreement between HbA1c and glucose in the general Dutch population: The New Hoorn Study. Diabetologia 51:S164 abstract </citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reiling</surname><given-names>E</given-names></name><name><surname>Vliet-Ostaptchouk</surname><given-names>JV</given-names></name><name><surname>Riet</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genetic association analysis of 13 nuclear-encoded mitochondrial candidate genes with type II diabetes mellitus: the DAMAGE Study</article-title><source>Eur J Hum Genet</source><year>2009</year></citation><citation citation-type="display-unstructured">Reiling E, van Vliet-Ostaptchouk JV, van &#x02019;t Riet E et al (2009) Genetic association analysis of 13 nuclear-encoded mitochondrial candidate genes with type II diabetes mellitus: the DAMAGE Study. Eur J Hum Genet. doi:10.1038/ejhg.2009.4 <pub-id pub-id-type="pmid">19209188</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="other">World Health Organization: Definition, diagnosis and classification of Diabetes Mellitus, Report of a WHO Consultation, Part 1: Diagnosis and classification of Diabetes Mellitus, WHO/NCD/NCS/99.2, Geneva. 1-1-1999</citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welschen</surname><given-names>L</given-names></name></person-group><article-title>Disease management for patients with type 2 diabetes: towards patient empowerment</article-title><source>Int J Integr Care</source><year>2008</year><volume>8</volume><fpage>e69</fpage></citation><citation citation-type="display-unstructured">Welschen L (2008) Disease management for patients with type 2 diabetes: towards patient empowerment. Int J Integr Care 8:e69 <pub-id pub-id-type="pmid">19008988</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Hitman</surname><given-names>G</given-names></name><etal/></person-group><article-title>Combining information from common type 2 diabetes risk polymorphisms improves disease prediction</article-title><source>PLoS Med</source><year>2006</year><volume>3</volume><fpage>e374</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0030374</pub-id></citation><citation citation-type="display-unstructured">Weedon MN, McCarthy MI, Hitman G et al (2006) Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 3:e374 <pub-id pub-id-type="pmid">17020404</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gauderman</surname><given-names>WJ</given-names></name></person-group><article-title>Sample size requirements for association studies of gene&#x02013;gene interaction</article-title><source>Am J Epidemiol</source><year>2002</year><volume>155</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1093/aje/155.5.478</pub-id></citation><citation citation-type="display-unstructured">Gauderman WJ (2002) Sample size requirements for association studies of gene&#x02013;gene interaction. Am J Epidemiol 155:478&#x02013;484 <pub-id pub-id-type="pmid">11867360</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><etal/></person-group><article-title>Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>2620</fpage><lpage>2628</lpage></citation><citation citation-type="display-unstructured">Chen WM, Erdos MR, Jackson AU et al (2008) Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 118:2620&#x02013;2628 <pub-id pub-id-type="pmid">18521185</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pare</surname><given-names>G</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><name><surname>Parker</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study</article-title><source>PLoS Genet</source><year>2008</year><volume>4</volume><fpage>e1000312</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1000312</pub-id></citation><citation citation-type="display-unstructured">Pare G, Chasman DI, Parker AN et al (2008) Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women&#x02019;s Genome Health Study. PLoS Genet 4:e1000312 <pub-id pub-id-type="pmid">19096518</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snieder</surname><given-names>H</given-names></name><name><surname>Sawtell</surname><given-names>PA</given-names></name><name><surname>Ross</surname><given-names>L</given-names></name><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Leslie</surname><given-names>RD</given-names></name></person-group><article-title>HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><fpage>2858</fpage><lpage>2863</lpage><pub-id pub-id-type="doi">10.2337/diabetes.50.12.2858</pub-id></citation><citation citation-type="display-unstructured">Snieder H, Sawtell PA, Ross L, Walker J, Spector TD, Leslie RD (2001) HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes 50:2858&#x02013;2863 <pub-id pub-id-type="pmid">11723071</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simonis-Bik</surname><given-names>AM</given-names></name><name><surname>Eekhoff</surname><given-names>EM</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><etal/></person-group><article-title>The heritability of HbA1c and fasting blood glucose in different measurement settings</article-title><source>Twin Res Hum Genet</source><year>2008</year><volume>11</volume><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1375/twin.11.6.597</pub-id></citation><citation citation-type="display-unstructured">Simonis-Bik AM, Eekhoff EM, Diamant M et al (2008) The heritability of HbA1c and fasting blood glucose in different measurement settings. Twin Res Hum Genet 11:597&#x02013;602 <pub-id pub-id-type="pmid">19016616</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>DCS</term><def><p>Diabetes Care System West Friesland</p></def></def-item><def-item><term>FPG</term><def><p>Fasting plasma glucose</p></def></def-item><def-item><term>SNP</term><def><p>Single-nucleotide polymorphism</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1007/s00125-009-1413-9) contains supplementary material, which is available to authorised users.</p></fn></fn-group></back></article> 